구조모아 (StructureMoa)항암 chemical structure spider web
방문EisaiBiogen
분석
큐레이션 브리핑
경쟁 포지션: Head-to-head with Kisunla; differs on titration, dosing interval, and stopping rules.
기전. Binds soluble amyloid-beta protofibrils and promotes microglial clearance of aggregated amyloid, reducing plaque burden and downstream tau and neurodegeneration markers.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
Amyloid-beta protofibrils
Early symptomatic Alzheimer's disease (MCI or mild dementia) with confirmed amyloid pathology
US, EU, JP, CN
Approved
leqembi · lecanemab · Leqembi · BAN2401 · lecanemab-irmb
2026-09-10
Data Confidence · High
Development Signal · Established
Humanized IgG1 monoclonal antibody
Selective binding to soluble amyloid-beta protofibrils over monomer and mature plaque
Protofibril selectivity targets the species most closely tied to synaptic toxicity, with lower ARIA-E rates than plaque-directed antibodies at comparable clearance.
구조화 데이터
Protofibril selectivity targets the species most closely tied to synaptic toxicity, with lower ARIA-E rates than plaque-directed antibodies at comparable clearance.
Amyloid clearance does not fully arrest tau pathology, so clinical benefit is partial rather than disease-arresting.
Humanized IgG1 monoclonal antibody
Amyloid-beta protofibrils · Amyloid PET centiloid reduction, plasma p-tau181/217, CSF Aβ42/40 ratio.
ARIA surveillance with MRI; ApoE ε4 genotyping before treatment
Head-to-head with Kisunla; differs on titration, dosing interval, and stopping rules.
MCI or mild dementia due to Alzheimer's disease with amyloid confirmed by PET or CSF
First disease-modifying therapy
IV infusion; subcutaneous maintenance under development
10 mg/kg q2w, with q4w maintenance option
ARIA surveillance with MRI; ApoE ε4 genotyping before treatment
Head-to-head with Kisunla; differs on titration, dosing interval, and stopping rules.
Binds soluble amyloid-beta protofibrils and promotes microglial clearance of aggregated amyloid, reducing plaque burden and downstream tau and neurodegeneration markers.
Fc-mediated microglial phagocytosis of amyloid aggregates.
Amyloid PET centiloid reduction, plasma p-tau181/217, CSF Aβ42/40 ratio.
Amyloid clearance does not fully arrest tau pathology, so clinical benefit is partial rather than disease-arresting.
구조화 데이터
Human
~5–7 days
Amyloid PET SUVR, plasma p-tau217, CDR-SB and ADAS-Cog trajectory
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA accelerated approval
APPROVAL · 2023년 1월
FDA traditional approval on CLARITY AD
APPROVAL · 2023년 7월
Monthly IV maintenance dosing added
APPROVAL · 2025년 1월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
EisaiBiogen
분석
큐레이션 브리핑
경쟁 포지션: Head-to-head with Kisunla; differs on titration, dosing interval, and stopping rules.
기전. Binds soluble amyloid-beta protofibrils and promotes microglial clearance of aggregated amyloid, reducing plaque burden and downstream tau and neurodegeneration markers.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
Amyloid-beta protofibrils
Early symptomatic Alzheimer's disease (MCI or mild dementia) with confirmed amyloid pathology
US, EU, JP, CN
Approved
leqembi · lecanemab · Leqembi · BAN2401 · lecanemab-irmb
2026-09-10
Data Confidence · High
Development Signal · Established
Humanized IgG1 monoclonal antibody
Selective binding to soluble amyloid-beta protofibrils over monomer and mature plaque
Protofibril selectivity targets the species most closely tied to synaptic toxicity, with lower ARIA-E rates than plaque-directed antibodies at comparable clearance.
구조화 데이터
Protofibril selectivity targets the species most closely tied to synaptic toxicity, with lower ARIA-E rates than plaque-directed antibodies at comparable clearance.
Amyloid clearance does not fully arrest tau pathology, so clinical benefit is partial rather than disease-arresting.
Humanized IgG1 monoclonal antibody
Amyloid-beta protofibrils · Amyloid PET centiloid reduction, plasma p-tau181/217, CSF Aβ42/40 ratio.
ARIA surveillance with MRI; ApoE ε4 genotyping before treatment
Head-to-head with Kisunla; differs on titration, dosing interval, and stopping rules.
MCI or mild dementia due to Alzheimer's disease with amyloid confirmed by PET or CSF
First disease-modifying therapy
IV infusion; subcutaneous maintenance under development
10 mg/kg q2w, with q4w maintenance option
ARIA surveillance with MRI; ApoE ε4 genotyping before treatment
Head-to-head with Kisunla; differs on titration, dosing interval, and stopping rules.
Binds soluble amyloid-beta protofibrils and promotes microglial clearance of aggregated amyloid, reducing plaque burden and downstream tau and neurodegeneration markers.
Fc-mediated microglial phagocytosis of amyloid aggregates.
Amyloid PET centiloid reduction, plasma p-tau181/217, CSF Aβ42/40 ratio.
Amyloid clearance does not fully arrest tau pathology, so clinical benefit is partial rather than disease-arresting.
구조화 데이터
Human
~5–7 days
Amyloid PET SUVR, plasma p-tau217, CDR-SB and ADAS-Cog trajectory
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA accelerated approval
APPROVAL · 2023년 1월
FDA traditional approval on CLARITY AD
APPROVAL · 2023년 7월
Monthly IV maintenance dosing added
APPROVAL · 2025년 1월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.